Cadrenal Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	6.57	8.4	0.03
Cash & Cash Equivalents	6.57	8.4	0.03
Cash Growth	63.00%	25685.61%	-
Other Current Assets	0.46	0.09	0.7
Total Current Assets	7.03	8.49	0.73
Property, Plant & Equipment	0.02	0.02	0.04
Other Long-Term Assets	0	0	0.01
Total Long-Term Assets	0.02	0.03	0.05
Total Assets	7.05	8.52	0.78
Accounts Payable	0.4	0.17	0.4
Current Debt	0.02	0.02	0.07
Other Current Liabilities	0.44	0.64	0.86
Total Current Liabilities	0.86	0.83	1.33
Long-Term Debt	0	0	0.57
Other Long-Term Liabilities	0	0	4.42
Total Long-Term Liabilities	0	0	4.99
Total Liabilities	0.86	0.83	6.33
Total Debt	0.02	0.02	0.64
Debt Growth	-60.43%	-96.67%	-
Retained Earnings	-16.73	-15.07	-6.71
Shareholders' Equity	6.19	7.69	-5.55
Net Cash / Debt	6.55	8.38	-0.61
Net Cash / Debt Growth	64.19%	-	-
Net Cash Per Share	0.41	0.62	-0.08
Working Capital	6.17	7.67	-0.61
Book Value Per Share	0.39	0.57	-0.70

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).